10 completed. 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 10 |
Follow Japanese Encephalitis: new trials by email Literature Review of Japanese Encephalitis trials Research Report on Japanese Encephalitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age JEVAX, JECEVAX - Japanese Encephalitis | Phase 2 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 220 | 2017-06-02 | 2018-09-17 |
| Safety and Immunogenicity of JECEVAX in Young Children JEVAX, JECEVAX-1, JECEVAX-0.8 - Japanese Encephalitis | Phase 2 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 200 | 2015-04-01 | 2016-06-28 |
| Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)] - Japanese Encephalitis | Phase 2 | Completed | University of Liverpool | 22 | 2009-05-01 | 2013-05-21 |
| Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28), Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28) - Japanese Encephalitis, Hepatitis A | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2008-03-01 | 2014-10-02 |
| Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age ChimeriVax™-JE, Japanese Encephalitis Inactivated Mouse Brain Vaccine - Japanese Encephalitis | Phase 2 | Completed | Sanofi | 96 | 2007-01-01 | 2012-08-27 |
| A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX ChimeriVax™-JE vaccine, JE-VAX® vaccine - Japanese Encephalitis | Phase 2 | Completed | Sanofi | 60 | 2005-05-01 | 2012-08-20 |
| Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine Live attenuated Japanese encephalitis virus, ChimeriVax™ diluent (Placebo) - Japanese Encephalitis | Phase 2 | Completed | Sanofi | 128 | 2004-11-01 | 2012-12-05 |
| Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) Live attenuated Japanese encephalitis virus; Yellow fever virus, Yellow fever virus; Live attenuated Japanese encephalitis virus - Japanese Encephalitis, Yellow Fever | Phase 2 | Completed | Sanofi | 108 | 2004-07-01 | 2012-09-20 |
| A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults Live attenuated Japanese encephalitis virus, then ChimeriVax diluent, ChimeriVax diluent, then Live attenuated Japanese encephalitis virus - Encephalitis, Japanese Encephalitis | Phase 2 | Completed | Sanofi | 202 | 2003-04-01 | 2012-07-16 |
| Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers Three 1 mL doses of Rabies vaccine and two JE vaccine, Three 0.5 mL doses of Rabies vaccine and two JE vaccine, Three 0.1mL doses of Rabies Vaccine and two JE vaccine - Rabies, Japanese Encephalitis | Phase 2 | Completed | Novartis | 200 | 2002-08-01 | 2008-06-10 |
Encephalitis, Japanese (10) · Encephalitis (1) · Hepatitis A (1) · Rabies (1) · Yellow Fever (1)
Arbovirus Infections (10) · Brain Diseases (10) · Central Nervous System Diseases (10) · Central Nervous System Infections (10) · Central Nervous System Viral Diseases (10) · Encephalitis, Arbovirus (10) · Encephalitis, Viral (10) · Flaviviridae Infections (10) · Flavivirus Infections (10) · Infections (10) · Infectious Encephalitis (10) · Mosquito-Borne Diseases (10) · Nervous System Diseases (10) · Neuroinflammatory Diseases (10) · RNA Virus Infections (10)
Hepatitis A Vaccines (1) · Immunoglobulins, Intravenous (1) · Japanese Encephalitis Vaccines (1)
Sanofi (5) · National Institute of Hygiene and Epidemiology, Vietnam (2) · Novartis (1) · Sanofi Pasteur, a Sanofi Company (1) · University of Liverpool (1)
Australia (3) · Thailand (2) · Vietnam (2) · India (1) · Nepal (1) · United States (1)
Thiem D Vu, MD., PhD. (2) · Ajit Rayamajhi, MBBS, MD (1) · Anand Dubey, M.D (1) · Atul Shanker, Dr. (1) · Bakul B. Javadekar, M.D. (1) · Nancy L Abdou, MD (1) · Sam Nightingale, MRCP (1) · Tom Solomon, MRCP, PhD (1)
PMID 20856164, PMID 20864814, PMID 21150279, PMID 25886645, PMID 27686833, PMID 27815383